Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized pilot comparison of formoline L112 vs alli (orlistat 60 mg) in overweight and obese adults
2008-001692-30Phase 4Completed
- Sponsor
- Certmedica International GmbH
- Start
- Sep 2009
- Modality
- Small Molecules, Microbiome Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Overweight and obesity comparing alli (orlistat 60 mg) arm with formoline L112 arm (2 arms). Primary endpoint: Weight reduction at 12 weeks. Started Sep 2009; status: completed.
02
Drugs
orlistatpolyglucosamine l112
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on 2008-001692-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001692-30.